Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Deng
    Deng
  2. Shuman
    Shuman
  3. Postow
    Postow
  4. Houghton
    Houghton
  5. Halpern
    Halpern
  6. Abramson
    Abramson
  7. Francis
    Francis
  8. Rossi
    Rossi
  9. Coit
    Coit
  10. Jiang
    Jiang

Groups

  1. Department of Medicine (60)
  2. Melanoma and Immunotherapeutics Service (60)
  3. Solid Tumor Oncology Division (60)
  4. GSK Faculty (36)
  5. Melanoma Disease Management Team (18)
  6. Dermatology Service (17)
  7. Dermatology (17)
  8. Division of Subspecialty Medicine (17)
  9. Sloan Kettering Institute Faculty (14)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (13)
Search Within
  1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (36)
  2. Meeting Abstract (21)
  3. Correspondence (1)
  4. Editorial (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (60)
  2. Melanoma and Immunotherapeutics Service (60)
  3. Solid Tumor Oncology Division (60)
  4. GSK Faculty (36)
  5. Melanoma Disease Management Team (18)
  6. Dermatology (17)

More Groups

People
  1. Jedd Wolchok (28)
  2. Taha Merghoub (18)
  3. Liang Deng (12)
  4. Paul Chapman (12)
  5. Stewart Shuman (10)
  6. Michael Postow (9)

More People

Years
  1. 2023 (1)
  2. 2022 (4)
  3. 2021 (4)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (5)

More Years

Publications
  1. Lancet Oncology (25)
  2. Journal of Investigative Dermatology (24)
  3. Lancet (3)
  4. Ophthalmology (3)
  5. Cancer Genetics and Cytogenetics (1)
  6. Controlled Clinical Trials (1)

More Publications

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial
    Journal Article

    Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
    Journal Article

    Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F. S.; Schachter, J.; Pavlick, A. C.; Lewis, K. D.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Deficiency of soluble adenylyl cyclase facilitates carcinogenesis
    Meeting Abstract

    Ramos, L.; Diaz, A.; Nardin, C. A.; Shaw, F. M.; Merghoub, T.; Wolchok, J.; Lyssiotis, C.; Cantley, L. C.; Levin, L.; Buck, J.; more...
    Journal of Investigative Dermatology (2015)

    Fulltext@MSK | Save
  • Expanded access programmes: Patient interests versus clinical trial integrity
    Journal Article

    Lorigan, P.; Ascierto, P. A.; Dummer, R.; Eggermont, A. M.; Flaherty, K. T.; Garbe, C.; Gogas, H.; Hauschild, A.; Kefford, R. F.; Kirkwood, J. M.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
    Journal Article

    Robert, C.; Ribas, A.; Wolchok, J. D.; Hodi, F. S.; Hamid, O.; Kefford, R.; Weber, J. S.; Joshua, A. M.; Hwu, W. J.; Gangadhar, T. C.; more...
    Lancet (2014)

    Fulltext@MSK | Save
  • Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease
    Journal Article

    Sivendran, S.; Chang, R.; Pham, L.; Phelps, R. G.; Harcharik, S. T.; Hall, L. D.; Bernardo, S. G.; Moskalenko, M. M.; Sivendran, M.; Fu, Y.; more...
    Journal of Investigative Dermatology (2014)

    Fulltext@MSK | Save
  • Heat-inactivated modified vaccinia virus triggers Type I IFN production and inflammasome activation via cGAS/STING and AIM2-mediated cytosolic DNA sensing pathways
    Meeting Abstract

    Dai, P.; Wang, W.; Cao, H.; Fitzgerald, K. A.; Nunez, G.; Merghoub, T.; Shuman, S.; Deng, L.
    Journal of Investigative Dermatology (2014)

    Fulltext@MSK | Save
  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    Journal Article

    McArthur, G. A.; Chapman, P. B.; Robert, C.; Larkin, J.; Haanen, J. B.; Dummer, R.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Eradication of melanoma by intratumoral injection of attenuated vaccinia virus requires CD8+ T cells and combination of anti-CTLA-4 blockade and virotherapy enhances therapeutic efficacy in advanced melanoma
    Meeting Abstract

    Wu, X.; Dai, P.; Wang, W.; Avogadri, F.; Cao, H.; Parikh, T.; Jiang, X.; Halpern, A. C.; Houghton, A. N.; Shuman, S.; more...
    Journal of Investigative Dermatology (2013)

    Fulltext@MSK | Save
  • Modified vaccinia virus Ankara induces type I IFN induction in conventional dendritic cells through a STING-mediated cytosolic DNA sensing pathway that requires IRF3, IRF7 and IFNAR1
    Meeting Abstract

    Dai, P.; Wang, W.; Cao, H.; Avogadri, F.; Vance, R.; Merghoub, T.; Shuman, S.; Deng, L.
    Journal of Investigative Dermatology (2013)

    Fulltext@MSK | Save